

Please type a plus sign (+) inside this box →



JC02 PCT/PTO

09/807361
12 APR 2001

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	Unassigned
				Filing Date	April 12, 2001
				First Named Inventor	Karl RANSBERGER
				Group Art Unit	Unassigned - 1651
				Examiner Name	Unassigned
Sheet	1	of	1	Attorney Docket Number	210445

U.S. PATENT DOCUMENTS						
Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
JR	AA	DE	41 30 221	A1	Mucos Pharma GmbH	03/18/93	Abstract	
JR	AB	DE	43 02 060	A1	Mucos Pharma GmbH	07/28/94	Abstract	
JR	AC	WO	96/00082	A	Cortecs Limited	01/04/96		
JR	AD	DE	197 26 253	A1	Mucos Pharma GmbH	12/24/98	Abstract	
JR	AE	DE	197 26 255	A1	Mucos Pharma GmbH	12/24/98	Abstract	

OTHER - NON PATENT LITERATURE DOCUMENTS					Translation	
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.			Yes	No**
JR	AF	TARGONI et al., "Modulation of the activation threshold for autoreactive T cells via systemic enzyme therapy with Phlogenzym," 11 th European Congress on Multiple Sclerosis, <i>Journal of Neuroimmunology, Suppl. 1</i> , 66 (1995)				
JR	AG	WALD et al., "Proteolytic enzymes prevent B16 melanoma metastasizing in C57B16 mice," ECCO 10: The European Cancer Conference, Vienna, Austria, September 12-16, 1999, <i>European Journal of Cancer</i> , 35 (Suppl. 4), S371 (September, 1999)				

Examiner Signature		Date Considered	27 May 03
-----------------------	--	--------------------	-----------

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).